Comment to the founders’ sale of shares

The two founders of ODI Pharma AB (“ODI” or “Company”), Derek Simmross and Volker Wiederrich, yesterday sold a part of their respective holdings in the Company. The total sale amounts to 251,166 shares. The founders’ holdings prior to the IPO remains, and the founders have no intention to sell more than what has already been sold.

Derek Simmross, CEO, and Volker Wiederrich, Chairman of the Board, comment

“We have understood that the share sale we made yesterday has caused some concern. We want to clarify the reasons behind the sale, which are personal financial reasons as we have not, and do not in the near future intend to, take salary for the managerial work we do in the Company. We of course firmly believe in ODI Pharma and are very excited about the future of the Company.”

For more information on ODI Pharma, please contact:

Derek Simmross, CEO, ODI Pharma AB

E-mail: info@odipharma.com

ODI Pharma AB

ODI Pharma, based on its European network, subsidiaries and affiliates, is a producer of finished pharmaceutical cannabis products with a focus on distribution to the medical cannabis market in Europe through its subsidiary ODI Pharma Polska Sp. z o.o. ODI Pharma intends to provide a high-quality product at a competitive price compared to competitors in Poland, thereby becoming the number one provider of medical cannabis in Poland. ODI Pharma also strives to be on the forefront of understanding the medical applications of the product as well as introducing new, innovative products to the European patients in need. The Company will continue to team up with the most knowledgeable and best renown partners in the industry to achieve its goals.